CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant by Kaninia, Stefania et al.
                          Kaninia, S., Grammatikos, A., Urankar, K., Renowden, S., Patel, N.,
Gompels, M., & Rice, C. M. (2021). CNS demyelination associated
with immune dysregulation and a novel CTLA-4 variant. Multiple
Sclerosis Journal. https://doi.org/10.1177/1352458520963896
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1177/1352458520963896
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via SAGE Publications
at https://journals.sagepub.com/doi/full/10.1177/1352458520963896 . Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the












© The Author(s), 2021. 
 




Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is 
CD28 homologue which negatively regulates T-cell 
activation and promotes tolerance; in contrast to 
CD28, CTLA-4 binding fails to stimulate T cells. 
Indeed, CTLA-4 variants are recognised to cause 
immune dysregulation disorders and CTLA-4 block-
ade is employed in cancer therapy. However, the use 
of CTLA-4 checkpoint inhibitors has been compli-
cated by the emergence of autoimmunity, including 
demyelination.1 We report the first case of biopsy-
proven central nervous system (CNS) inflammatory 
demyelination in the context of primary immunodefi-
ciency and a novel CTLA-4 variant.
Case report
A 51-year-old woman presented with a 3-week history 
of poor balance, nausea and right-sided facial sensory 
disturbance. Her medical history was significant for 
bronchiectasis, necrotising granulomatous lymphadeni-
tis, iron deficiency anaemia, eczema, idiopathic throm-
bocytopenic purpura, recurrent sinusitis, osteonecrosis 
of the jaw induced by bisphosphonates, diverticulitis, 
bowel salt malabsorption and vitamin D deficiency. 
The patient’s daughter had recurrent episodes of CNS 
inflammation as a child and in adulthood she developed 
autoimmune hepatitis, autoimmune haemolytic anaemia 
and bronchiectasis. The patient’s son was known to have 
type I diabetes, thyroid disease, pernicious anaemia and 
autoimmune encephalitis. FAS sequencing for autoim-
mune lymphoproliferative syndrome (ALPS) was nor-
mal and, at the time of presentation, extended panel 
screening for primary immunodeficiency was ongoing. 
There was prior exposure to corticosteroids but no other 
immunomodulatory treatment.
On examination, there was reduced light touch sensa-
tion in the mandibular and maxillary distribution of 
the right trigeminal nerve with dysarthria, mild right 
upper limb weakness and dysmetria. Microcytosis 
(MCV 80.5 fL) with low ferritin (12 µg/L), lymphope-
nia (0.87 × 109/L) and hypogammaglobulinaemia 
(IgG 5.2 g/L) were noted. Cerebrospinal fluid (CSF) 
analysis showed mildly elevated protein concentra-
tion (0.75 g/L), with normal white cell count (4/mm3) 
and the presence of unmatched (type 2) oligoclonal 
bands indicative of intrathecal IgG synthesis. CSF 
cytology and flow cytometry were non-diagnostic. 
Screening for infection including atypical organisms 
was negative although low-level Epstein–Barr virus 
(EBV) DNA was detected in her serum (EBV PCR 95 
copies/mL; EBV DNA 1.98 log10 copies/mL). Brain 
magnetic resonance imaging (MRI) demonstrated a 
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gadolinium-enhancing lesion in the right cerebellar 
peduncle with surrounding oedema and effacement of 
the fourth ventricle (Figure 1(a) and (d)).
Given clinical concern regarding CNS lymphoma, 
cerebellar biopsy was offered but was initially 
declined by the patient. Empirical treatment with 
pulsed methylprednisolone was initiated with clini-
cal and radiological improvement (Figure 1(b)). 
However, relapse occurred on attempted corticoster-
oid wean; brain imaging demonstrated extension of 
the cerebellar lesion (Figure 1(c)). Biopsy of the 
right cerebellar peduncle lesion was subsequently 
performed. This demonstrated a florid active inflam-
matory and demyelinating process. The T-cell infil-
trate was composed of CD4 and CD8 cells 
(approximately 2:1) and an estimated 30%–40% of 
the CD4 cells co-expressed programmed cell death 
protein 1 (PD-1), indicating T-cell activation (Figure 
1(g)–(l)).
Subsequently, a virtual sub-panel of 194 genes asso-
ciated with primary immunodeficiencies screened 
using Agilent ‘Focused Exome’ custom target enrich-
ment system (SureSelectXT) and Next Generation 
Sequencing demonstrated that the patient (and her 
affected family members) were heterozygous for a 
novel, likely pathogenic frameshift deletion variant 
in CLTA-4 exon 1:c.81dup p.(leu28Serfs*32). An 
additional novel heterozygous missense variant was 
identified in the autosomal recessive gene LRBA in 
exon 42: c.642T>C, p.(Phe2142Leu) but was con-
sidered of uncertain clinical significance given that 
only bi-allelic function loss variants have been linked 
with disease previously.
Pulsed corticosteroid therapy and oral taper was ini-
tiated with clinical benefit and sirolimus (an mTOR 
inhibitor which blocks the CD28 signalling path-
way) was introduced as a steroid-sparing agent. 
Subsequently, the patient has been neurologically 
stable; reduced sensation in the maxillary nerve dis-
tribution on the right with a mild postural upper limb 
tremor but no eye signs or dysmetria. There has been 
resolution of neuroimaging changes and no recur-
rence of inflammatory CNS demyelination (Figure 
1(e) and (f)).
Discussion
Mendelian disorders of adaptive immunity have 
previously been reported to be associated with 
demyelination,2 and similarities reported in the 
aberrant peripheral B-cell responses of those with 
multiple sclerosis (MS) and immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX) 
syndrome are notable.3
In the largest case series reporting the clinical phe-
notype of CTLA-4 insufficiency, neurological 
involvement including autoimmune encephalitis or 
encephalomyelitis was reported in 28% of patients. 
This included three patients with cerebral perivascu-
lar lymphocytic infiltrates but, although demyelina-
tion was suspected clinically, this was not identified 
histologically.4 Here, we report CNS inflammatory 
demyelination and a novel, likely pathogenic CTLA-
4 frameshift deletion variant occurring in the context 
of primary immunodeficiency.
Increased CTLA-4 expression is protective in experi-
mental allergic encephalomyelitis.5 Although CTLA-4 
polymorphisms are unlikely to have a significant effect 
on MS susceptibility,6 the CTLA-4 polymorphism 
rs5742909 has been associated with reduced remyelina-
tion in MS7 and people with MS are known to have 
reduced expression of CTLA-4.8 Furthermore, therapeu-
tic use of immune checkpoint inhibitors acting via the 
CTLA-4 pathway has been associated with clinically 
relevant demyelination.1 Disappointingly however, 
abatacept, a humanised CTLA4-IgG fusion protein, 
failed to demonstrate benefit in relapsing-remitting MS 
although note is made of the small study size.9
Given that lymphoma occurs with increased inci-
dence in patients with autoimmunity including CTLA-
4 variants,4 there should be a low threshold to pursue 
a tissue diagnosis where there is evidence of neuroin-
flammation. This is particularly important given the 
delays in diagnosis which may be incurred following 
empirical corticosteroid treatment.10
This report of clinically relevant demyelination 
associated with an inflammatory T-cell infiltrate 
occurring in the context of a pathogenic CTLA-4 
variant, supports CTLA-4 as a regulator of T-cell 
activation and immune tolerance and is further evi-
dence that perturbation of the CTLA-4 pathway can 
cause clinically relevant inflammatory demyelina-
tion. This has significant implication for the devel-
opment of novel treatments for autoimmune 
conditions including MS but also emphasises the 
need for caution with clinical use of CTLA-4 
immune checkpoint inhibitors, particularly in those 
with a history of immune-mediated demyelination. 
Consideration should be given to screening for 
CTLA-4 variants in individuals with a history com-
patible with autoimmunity and CNS inflammatory 
disease, particularly following exclusion of 
lymphoma.
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Figure 1. Neuroimaging: (a–c, e) T2 axial MRI brain, (d) gadolinium-enhanced T1 axial MRI brain and (f) fluid-
attenuated inversion recovery (FLAIR) coronal MRI brain. (g–l) Histology of cerebellar white matter biopsy. 
Neuroimaging at presentation (a) demonstrated an intrinsic lesion in the right cerebellar peduncle with surrounding 
oedema which improved with corticosteroids (b) but relapsed on steroid wean (c). The intrinsic cerebellar lesion 
demonstrated nodular enhancement (d). Follow-up neuroimaging at 3 years shows a small focus of gliosis at the site of 
cerebellar biopsy with resolution of inflammatory changes (e and f). Histological examination of cerebellar white matter 
biopsy: (g) H&E 20× demonstrating moderate parenchymal mixed inflammatory infiltrate of lymphocytes, plasma cells, 
and microglia with perivascular cuffing by lymphocytes without underlying vasculitis. Inset highlighting perivascular 
infiltrate of atypical lymphocytes. (h) CD3 20× highlighting both a parenchymal and perivascular T-cell infiltrate. (j) 
Luxol fast blue 20× highlighting evidence of diffuse white matter demyelination without perivascular accentuation of 
myelin loss. (i) CD8 20× and (k) CD4 20× – demonstrating a 2:1 ratio of CD4:CD8 T cells. (l) PD-1 20×: 30%–40% of 
the CD4-positive cells co-express PD-1 in keeping with Helper T cells. Bar = 100 μm.
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